Pharma’s Cutting Edge

Leave a Reply

You must be logged in to post a comment.

Pages

• About

Recent Posts

• FDA finally admits need for large safety studies premarketing
• CB1 antagonist update, and a poor excuse
• Off-base on off-label promotion
• Acomplia to be pulled in EU
• Drug’s affected by Pfizer’s portfolio prioritization
• Lilly to Massachusetts legislators: your new code stinks

Pharma's Cutting Edge Archives

Select Month November 2008  (2) October 2008  (3) September 2008  (4) August 2008  (1) July 2008  (3) June 2008  (2) May 2008  (2) April 2008  (2) March 2008  (3) February 2008  (3) January 2008  (3) December 2007  (3) November 2007  (1) October 2007  (3) September 2007  (5) August 2007  (6) July 2007  (4) June 2007  (7) May 2007  (6) April 2007  (4) March 2007  (5) February 2007  (9) January 2007  (5) December 2006  (7) November 2006  (7) October 2006  (8) September 2006  (15) August 2006  (15) July 2006  (14) June 2006  (9) May 2006  (8) April 2006  (7) March 2006  (11) February 2006  (6) January 2006  (13) December 2005  (8) November 2005  (12) October 2005  (10) September 2005  (13) August 2005  (12) July 2005  (7) June 2005  (9) May 2005  (3) April 2005  (1) March 2005  (1) February 2005  (1) January 2005  (1)

Categories

Select Category Diagnostics etc.  (7) Drug Safety  (57) EMEA  (9) FDA  (74) For Investors  (81) Healthcare Delivery  (13) Legislation  (25) Lifecycle  (19)    Generics  (15) Miscellaneous  (31) Product Quality  (5) Public Perceptions  (64) R&D  (48)    Biostatistics  (8)    Clinical Research  (45)    Discovery  (17)    Preclinical  (4) Sales and Marketing  (37)    Health Econ  (13) Technology  (75)

Meta

• Register
• Log in
• Entries RSS
• Comments RSS
• WordPress.org

Blogroll

• Eye on FDA
• Health Affairs Blog
• Health Business Blog
• In the Pipeline
• In Vivo Blog
• Laszlo Letter
• Pharma Blogosphere
• Pharma Marketing Blog
• PharmaGossip
• Philly Pharm Bio Blog
• Scientific American Blog
• The Health Care Blog

Syndicate

•